MURRYSVILLE, Pa., May 15, 2015 /PRNewswire/ -- Respironics, Inc., a Philips business, today provided the following response to ResMed’s Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation ...
On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...
Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...
Medical device company ResMed Inc. RMD recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). According to ...
Royal Philips ($PHG) said it is working with ResMed ($RMD) to analyze study data from mid-May showing that the latter company's Adaptive Servo-Ventilation (ASV ...
Auto-Adjusting Pressure : The ResMed AirCurve 11 VAuto BiPAP machine features an automatic adjustment function that allows the device to change pressure settings based on real-time data. This ...
On Jun 19, 2015, we issued an updated research report on ResMed, Inc. RMD. Recently, ResMed faced a major blow as its phase III SERVE-HF study of ASV failed to meet its primary endpoint. In fact, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback